The Claim
Prostaglandin E2 signaling through the EP4 receptor in adipocytes sustains basal lipolysis during feeding-fasting cycles, leading to fibrosis, ectopic fat deposition, and insulin resistance in individuals with morbid obesity.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with morbid obesity, prostaglandin E2 acting on the EP4 receptor in fat cells maintains a baseline level of fat breakdown during normal eating and fasting cycles, which contributes to tissue scarring, fat accumulation in organs, and reduced insulin sensitivity.
See the scientific wording
Prostaglandin E2 signaling through the EP4 receptor in adipocytes sustains basal lipolysis during feeding-fasting cycles, contributing to fibrosis, ectopic fat deposition, and insulin resistance in individuals with morbid obesity.
After eating, insulin triggers fat cells to produce a chemical that binds to a specific receptor on their surface, keeping fat breakdown active even when the body should be storing fat. This constant fat breakdown overwhelms the fat tissue's ability to expand, causing scar tissue to form. The scarred fat tissue can no longer hold excess fat, so fat spills into the liver and muscles, where it interferes with insulin's ability to control blood sugar.
What the research says
1 studyIn people with severe obesity, a chemical signal called PGE2 tells fat cells to keep breaking down fat even after eating, which causes fat to build up in the liver and muscles and makes the body less able to use insulin properly. This study shows that blocking this signal might help prevent those problems.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.